KUALA LUMPUR (Feb 16): Yong Tai Bhd has denied rumours in the social media that its Covid-19 vaccine application has been rejected by the Ministry of Health’s (MoH) National Pharmaceutical Regulatory Agency.
“Yong Tai is still working closely with its Chinese partner to escalate the application process and urges all stakeholders to be patient and stop spreading untrue statement, given the importance of the vaccine to help the nation achieve herd immunity,” it said in a statement.
The group said it is escalating the application process for the Phase III clinical trial tests, while awaiting the compilation of data for the Phase I and II trials from Shenzhen Kangtai Biological Products Co Ltd by next week.
After getting the data, the group said it will submit the information to the MoH.
“Once the data and protocols are reviewed and approved by MoH, Yong Tai would then proceed with the Phase III clinical trials,” it added.
On Dec 4 last year, Yong Tai inked a heads of agreement with Shenzhen Kangtai for the development and exclusive commercialisation of the latter’s inactivated Covid-19 vaccine in Malaysia. On Feb 5, the group signed the definitive agreement.
Yong Tai intends to supply 100 million doses of the vaccine over a five-year period.
Shares of Yong Tai closed 0.5 sen or 2.22% lower at 22 sen yesterday, for a market capitalisation of RM263.61 million.
Get the latest news @ www.EdgeProp.my
Subscribe to our Telegram channel for the latest stories and updates